

2026 Genitourinary Cancers Symposium Program Committee

All relationships are considered compensated. Relationships are self-held unless otherwise noted.

I = Immediate Family Member, Inst = My Institution

Name	Employment	Leadership	Stock and Other Ownership Interests	Honoraria	Consulting or Advisory Role	Speakers' Bureau	Research Funding	Patents, Royalties, Other Intellectual Property	Expert Testimony	Travel, Accommodations, Expenses	Other Relationship	(OPTIONAL) Uncompensated Relationships	(OPTIONAL) Open Payments Link
Andrea B. Apolo													
Leslie K. Ballas	Cedars Sinai Medical Center			Up-To-Date	Johnson and Johnson MDHealth UroToday		Astellas Pharma						
Pedro C. Barata			Luminate Medical	Medscape UroToday	Astellas Medivation AstraZeneca AVEO Bayer Bristol-Myers Squibb Caris Life Sciences Dendreon (Inst) Eisai EMD Serono Exelbix Ipsen Merck Novartis Pfizer	Astellas Pharma AstraZeneca	AVEO (Inst) Blueearth (Inst) Exelbix Merck (Inst) Pfizer (Inst)						
Katy Beckermann					Adicet Bio Aravive Arcus Biosciences AstraZeneca AVEO Bristol-Myers Squibb Eisai Exelbix Janssen Oncology Merck Nimbus Novartis Pfizer Xencor		Aravive (Inst) Arsenal (Inst) Bristol-Myers Squibb Pionyr (Inst)						
Peter C. Black					Astellas Pharma AstraZeneca Aura Biosciences Bayer Bristol-Myers Squibb Combat Medical EMD Serono Ferring Janssen Oncology Merck Nanobot NanoOlogy Nonagen Bioscience Pfizer Photocure Prokarium Sumitomo Pharma Oncology TerSera Tolmar Tyra Biosciences Verity Pharmaceuticals	Bayer Janssen Oncology Pfizer TerSera		1. PCT/CA2014/000787. Canada, 2014-11-03 Cancer Biomarkers and Classifiers and uses thereof. 2. #61899648 United States. 2013-03-13 Bladder cancer signature.					
Alberto Bossi				Accord Healthcare Astellas Pharma Ferring Ipsen Janssen Myovan RECORDATI	Elekta	Astellas/Agensys Elekta Ipsen				Astellas Pharma Elekta Ipsen			
Mauricio Burotto					MSD Oncology	AstraZeneca Bristol-Myers Squibb				BMSi			
Ronald C. Chen	University of Kansas Medical Center				Abbvie Accuray Astellas Pharma Bayer Blue Earth Diagnostics Genetech Janssen Medivation/Astellas Myovant Sciences Pfizer VIR Biotechnology		Accuray			Reflexion Medical Telix Pharmaceuticals			
Marc Dall'Era						Photocure	Janssen						
Tanya B. Dorff					Abbvie Astellas Pharma AstraZeneca Bayer Janssen Oncology Novartis Pfizer		Abbvie (Inst) Amgen (Inst) AstraZeneca (Inst) Hookipa Biotech (Inst) Janssen Oncology (Inst) Promontory Therapeutics (Inst)						
John L. Gore					Astellas Pharma								
Peter Hoskin							Astellas Pharma (Inst) Bayer (Inst) Bristol-Myers Squibb (Inst) Elekta (Inst) Pfizer (Inst) Roche (Inst) Varian Medical Systems (Inst)						

Jose A. Karam	MD Anderson Cancer Center MD Anderson Physician's Network		Medtek ROM Technologies	American Board of Urology American Urological Association ECRI Medscape Merck Pfizer Specialty Networks Syapse Telix Pharmaceuticals	American Board of Urology American Urological Association ECRI Medscape Merck Pfizer Specialty Networks Syapse Telix Pharmaceuticals		Elypta (Inst) Merck (Inst) Mirati Therapeutics (Inst) Roche/Genentech (Inst)			American Board of Urology American Urological Association			
Brandon A. Mahal				Foundation Medicine							American Society for Radiation Oncology Department of Defense-Prostate Cancer Research Program Prostate Cancer Foundation		
Katie S. Murray					Johnson and Johnson Urogen pharma	Ferring Pharmaceuticals Urogen pharma							
Atul B. Shinagare				Arog	Imaging Endpoints Virtualscopics								
Aradhana M. Venkatesan											Dept. of Defense (Inst) Ingram Family Fund (UT MD Anderson Cancer Center) (Inst) Joint Center for Computational Oncology (UTMDACC Institute for Data Science in Oncology, UT Austin Oden Institute for Computational Engineering and Sciences & Texas Advanced Computing Center) Joint Center for Computational Oncology (UTMDACC Institute for Data Science in Oncology, UT Austin Oden Institute for Computational Engineering and Sciences & Texas Advanced Computing Center) UT MD Anderson Cancer Center (Inst)		

2026 Genitourinary Cancers Symposium Abstract Graders

All relationships are considered compensated. Relationships are self-held unless otherwise noted.

I = Immediate Family Member, Inst = My Institution

Name	Employment	Leadership	Stock and Other Ownership Interests	Honoraria	Consulting or Advisory Role	Speakers' Bureau	Research Funding	Patents, Royalties, Other Intellectual Property	Expert Testimony	Travel, Accommodations, Expenses	Other Relationship	(OPTIONAL) Uncompensated Relationships	(OPTIONAL) Open Payments Link
Yüksel Ürün				Abdi Ibrahim Astellas Pharma AstraZeneca Bristol-Myers Squibb Eczacıbasi Gen İlaç Gilead Sciences Janssen Merck Sharp & Dohme Merck Serono Novartis Pfizer Roche	Abdi Ibrahim Astellas Pharma AstraZeneca Bristol-Myers Squibb Eczacıbasi Gen İlaç Gilead Sciences Janssen Merck Sharp & Dohme Merck Serono Novartis Pfizer Roche	Abdi Ibrahim Astellas Pharma AstraZeneca Bristol-Myers Squibb Eczacıbasi Gen İlaç Janssen Merck Sharp & Dohme Merck Serono Novartis Pfizer Roche			Abdi Ibrahim Bristol-Myers Squibb Eczacıbasi Gen İlaç Pfizer Roche				
Christos Kyriakopoulos	Epic Systems (I)		Epic Systems (I) Biogen, Inc		AVEO EMD Serono Exelixis Janssen Oncology Pfizer Sanofi		AstraZeneca Bristol Myers Squibb Foundation EMD Serono ESSA Pharma Inc Gilead Sciences Madison Vaccines, Inc Pionyr Sanofi-Aventis						
Wenxin Xu					AVEO Caldara Medical Daiichi Sankyo Eisai Exelixis Jazz Pharmaceuticals Merck Xencor		ArsenalBio (Inst) Merck (Inst) Oncohost (Inst)						
Karie Runcie					Johnson & Johnson/Janssen		Amgen (Inst) Bristol-Myers Squibb (Inst) Exelixis (Inst) Novartis (Inst)						
Shilpa Gupta					Astellas Pharma AstraZeneca Bristol-Myers Squibb/Medarex Foundation Medicine Johnson & Johnson/Janssen Merck Natera Novartis Pfizer		Acvion Therapeutics (Inst) Amgen (Inst) Bristol Myers Squibb Foundation (Inst) Convergent Therapeutics (Inst) Exelixis (Inst) Flare Therapeutics (Inst) Merck (Inst) Pfizer (Inst) Roche/Genentech (Inst) Tyra Biosciences (Inst)	UpToDate author royalty		Astellas Pharma Merck Pfizer			